Navigation Links
MiddleBrook Pharmaceuticals Reports Fourth Quarter and Full Year 2007 Results
Date:3/4/2008

es affiliated with

Deerfield Management pursuant to the Keflex transaction, resulting from

MiddleBrook's consolidation of the two affiliates under Financial

Accounting Standards Board Interpretation No. 46 (revised 2003)

"Consolidation of Variable Interest Entities."

-- Net loss per share applicable to common stockholders for the fourth

quarter of 2007 was ($0.19), compared to a loss per common share of

($0.22) in the prior quarter and ($0.44) in the fourth quarter of 2006.

For the fiscal year of 2007, net loss per share applicable to common

stockholders was ($0.96), down from ($1.38) for the fiscal year of

2006.

Per share figures were computed on the basis of an average of 46.7

million shares outstanding in the fourth quarter of 2007, 46.7 million

shares outstanding in the third quarter of 2007, 31.5 million shares

outstanding in the fourth quarter of 2006; and 43.8 million shares

outstanding for the full year of 2007 and 30.5 million shares

outstanding for the full year of 2006.

-- Cash and marketable securities decreased by $4.0 million during the

fourth quarter. Changes were composed of $6.9 million of operating

losses, $4.9 million in loan payments, and $2.3 million for working

capital changes and other items; offset by $7.0 million raised from the

Deerfield Management Keflex transaction and $3.1 million for non-cash

expenses.

-- The Balance Sheet at the end of 2007 reflected $2.0 million of

unrestricted cash, cash equivalents and marketable securities, compared

to $15.4 million as of year-end 2006. Following the fourth quarter of

2007, MiddleBrook completed a private placement of common stock and

warrants resulting in the addition of $19.9 million of net proceeds to

the Company.

FINANCIAL GUIDANCE

Total r
'/>"/>

SOURCE MiddleBrook Pharmaceuticals, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15

Related biology technology :

1. MiddleBrook Pharmaceuticals Closes Private Placement of Common Equity Raising $21 Million
2. MiddleBrook Pharmaceuticals to Present at BIO CEO & Investor Conference 2008
3. MiddleBrook Pharmaceuticals to Announce Fourth Quarter and Full Year 2007 Financial Results on March 4, 2008
4. Vion Pharmaceuticals Pays Interest on 7.75% Convertible Senior Notes
5. China Biopharmaceuticals Holdings Announces Second Quarter 2007 Financial Results
6. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
7. XTL Biopharmaceuticals Announces Financial Results for the Six Months Ended June 30, 2007
8. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
9. Nabi Biopharmaceuticals to Present at Upcoming Industry Conferences
10. Anadys Pharmaceuticals Appoints Steve Worland, Ph.D. as President and Chief Executive Officer
11. Poniard Pharmaceuticals Announces Participation in Upcoming Conferences
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/28/2014)... 2014 Supplementing their complete line ... for Eppendorf Safe Lock Centrifuge Tubes . ... highest quality tubes at an affordable price. Eppendorf ... doing chemical, medical, pharmaceutical, and life science research ... regularly able to afford Eppendorf products. , Eppendorf ...
(Date:8/27/2014)... Green & Grow Inc. (GGI) has raised an ... Otter Capital as a significant new partner. Otter Capital’s ... Agriplier™ technology, building on recent compelling field trial results ... meeting, we have been impressed with Otter Capital’s knowledge ... Sobba, President and CEO of GGI. “We look forward ...
(Date:8/27/2014)... 2014 Reportlinker.com announces that a ... its catalogue: Global Biodegradable Packaging ... http://www.reportlinker.com/p02316661/Global-Biodegradable-Packaging-Materials-Market-2014-2018.html About Biodegradable Packaging ... readily decomposed by the action of microorganisms. ... in terms of raw materials, production technology, ...
(Date:8/27/2014)... Dallas, TX (PRWEB) August 27, 2014 ... professional and in-depth study on the current state of ... The report provides a basic overview of the industry, ... analysis and Chinese domestic market analysis are provided with ... of the market. A comparison between the international and ...
Breaking Biology Technology:Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 2Eppendorf Safe Lock Centrifuge Tube Promotion Now Available at Major Pipette Distributor Pipette.com 3Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 2Green & Grow Inc. Secures $6M Series B Funding from Otter Capital 3Global Biodegradable Packaging Materials Market 2014-2018 2Global Biodegradable Packaging Materials Market 2014-2018 3Global Biodegradable Packaging Materials Market 2014-2018 4Global Biodegradable Packaging Materials Market 2014-2018 5Global Biodegradable Packaging Materials Market 2014-2018 6Global Biodegradable Packaging Materials Market 2014-2018 7Trifluoroacetic Acid Industry (Asia, Europe, North America, ROW) Analysis Report Now Available at ReportsnReports.com 2
... for site-directed mutagenesis of,large plasmids , ... Hogrefe ,Jeff Braman ,Stratagene , The QuikChange ... 80%. We have created a new kit ... XL,site-directed mutagenesis kit has ...
... , Reliable Assessment of Micronuclei for Genotoxicity Testing ... micronucleus analysis made easy with the,icroFlow Micronucleus Analysis ... R. Tometsko ,Litron Laboratories, Rochester, NY , Mark ... Kit provides researchers with the,necessary reagents and supplies ...
... PCR Performance Comparisons Between PfuTurbo and Taq DNA ... superior choice for robust,high-fidelity PCR amplification , ... Janice Cline ,Stratagene , In this update, we ... , and Taq DNA polymerase. ,PCR ...
Cached Biology Technology:High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 2High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 3High-Efficiency Site-Directed Mutagenesis of Large Plasmid Vectors 4Reliable Assessment of Micronuclei for Genotoxicity Testing in Mice or Rats 2Reliable Assessment of Micronuclei for Genotoxicity Testing in Mice or Rats 3Reliable Assessment of Micronuclei for Genotoxicity Testing in Mice or Rats 4Reliable Assessment of Micronuclei for Genotoxicity Testing in Mice or Rats 5PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 2PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 3PCR Performance Comparisons Between pfuturbo and Taq DNA,Polymerases 4
(Date:8/28/2014)... 2014A new method for measuring and imaging how quickly ... researchers better understand how drug abuse affects the brain, ... engineering, and lead to better treatment options for recovering ... of researchers from Stony Brook University in New York, ... published today in The Optical Society,s (OSA) open-access journal ...
(Date:8/28/2014)... a significant health risk to people with asthma according to ... and Clinical Immunology . , By critically reviewing the findings ... found that the presence of several types of mould can ... increasing the likelihood of developing the condition. , The research ... Exeter Medical School and is the first time all of ...
(Date:8/28/2014)... Biologists at Ludwig-Maximilians-Universitaet (LMU) in Munich have assigned ... genus of predatory arthropods. These animals lived in ... than related forms found in Jurassic strata. ... their shallow marine habitat and were fossilized some ... other denizens of the Silurian seas although ...
Breaking Biology News(10 mins):This is your brain's blood vessels on drugs 2This is your brain's blood vessels on drugs 3Indoor mold poses health risk to asthma sufferers 2Paleontology: Oldest representative of a weird arthropod group 2
... comes to the deadly skin cancer melanoma, studying ... provide insight into the disease's development, according to ... predoctoral fellow at Stanford University School of Medicine. ... melanoma development, scientists have not been able to ...
... cancer melanoma, studying functional tissue rather than cell ... development, according to new research from a Howard ... School of Medicine. , Though multiple genetic alterations ... been able to establish a direct causal link ...
... of the Spinal Injuries Research Centre at the Prince ... by the Christopher Reeve Paralysis Foundation to prepare a ... the next two years. , Christopher Reeve met with ... and was impressed with their work in spinal injuries ...
Cached Biology News:Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance 2Researchers use RNAi libraries to identify regulators of apoptosis and chemoresistance 3Engineered skin offers clues to melanoma development 2Engineered skin offers clues to melanoma development 33D Atlas Will Help Navigate The Spinal Cord 2
... atoms at the 3, 3', 4, and ... as an internal standard for the quantification ... PGE1 is the theoretical cyclooxygenase metabolite of ... undetectable in the plasma of normal humans ...
Acrylamide, 500 g. Assay: > 99.9%, acrylic acid: < 0.001%. Conductivity (35%): < 2 umhos/cm.Risks: 45, 46, 48, 23, 24, 25 ; Safety Precautions: 53, 44. Category: Nucleotides & Enzymes & Biochemicals...
Direct ELISA Assay Diluent, 10 L...
Direct ELISA Assay Diluent - EDTA, 10 L...
Biology Products: